Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 9/20 | 0.67 |
| ▸ | KDR | P35968 | 3/20 | 0.67 |
| ▸ | CDK8 | P49336 | 3/20 | 0.66 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA7 | P43166 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.60 |
| ▸ | RET | P07949 | 1/20 | 0.60 |
| ▸ | BRAF | P15056 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sc-43 SCHEMBL14684295 | 1.00 | RAF1 (0.67) | RAF1KDRCDK8CA1CA2 | |
| Sc-43 SCHEMBL29492117 | 1.00 | RAF1 (0.67) | RAF1KDRCDK8CA1CA2 | |
| SCHEMBL18615606 | 0.94 | RAF1 (0.59) | RAF1KDRCDK8CA1CA2 | |
| SCHEMBL15746582 | 0.92 | KDR (0.74) | RAF1KDRCDK8CA1CA2 | |
| SCHEMBL16480213 | 0.92 | RAF1 (0.56) | RAF1KDRCDK8CA1CA2 | |
| SCHEMBL16620784 | 0.92 | KDR (0.73) | RAF1KDRCDK8CA7CA9 | |
| SCHEMBL18615962 | 0.90 | KDR (0.67) | RAF1KDRCDK8CA1CA2 | |
| SCHEMBL18615686 | 0.89 | CDK8 (0.65) | RAF1KDRCDK8CA1CA2 | |
| SCHEMBL18616000 | 0.87 | KDR (0.64) | RAF1KDRCDK8CA1CA2 | |
| SCHEMBL18615368 | 0.87 | BRAF (0.59) | RAF1KDRCDK8CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12514938-B2 | Fibroblast activation protein targeting peptides | PERSPECTIVE THERAPEUTICS, INC. (US) | 2026-01-06 | — | — | US | claimed |
| US-20250332296-A1 | ZWITTERIONIC METAL CHELATORS | CURADEL SURGICAL INNOVATIONS, INC. (US) | 2025-10-30 | — | — | US | claimed |
| EP-4619043-B1 | FIBROBLAST ACTIVATION PROTEIN TARGETED COMPOUNDS AND USE THEREOF | PERSPECTIVE THERAPEUTICS INC (US) | 2025-10-29 | — | — | EP | claimed |
| EP-4619043-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED COMPOUNDS AND USE THEREOF | Perspective Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4611825-A1 | RADIOPHARMACEUTICAL MOFS FOR MEDICAL IMAGING | Node Pharma AS (NO) | 2025-09-10 | — | — | EP | claimed |
| US-20250262335-A1 | PSMA-Targeting Ligands with Optimal Properties for Imaging and Therapy | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2025-08-21 | — | — | US | claimed |
| WO-2025128149-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED COMPOUNDS AND USE THEREOF | VIEWPOINT MOLECULAR TARGETING, INC. (US) | 2025-06-19 | — | — | WO | claimed |
| US-20250186630-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES | VIEWPOINT MOLECULAR TARGETING, INC. (US) | 2025-06-12 | — | — | US | claimed |
| WO-2025119203-A1 | HETERODIMER RADIONUCLIDE DRUG CONJUGATE, AND PREPARATION THEREFOR AND USE THEREOF | 烟台蓝纳成生物技术有限公司 | 2025-06-12 | — | — | WO | claimed |
| US-20250186632-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES | VIEWPOINT MOLECULAR TARGETING, INC. | 2025-06-12 | — | — | US | claimed |
| EP-4326246-A1 | PSMA-TARGETING LIGANDS WITH OPTIMAL PROPERTIES FOR IMAGING AND THERAPY | Wisconsin Alumni Research Foundation (US) | 2024-02-28 | — | — | EP | claimed |
| CN-117180254-A | Application of SC-43 in preparation of medicine for resisting gram-positive bacterial infection | 华中科技大学协和深圳医院 | 2023-12-08 | — | — | CN | claimed |
| US-20230302164-A1 | PSMA-Targeting Ligands With Optimal Properties for Imaging and Therapy | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-09-28 | — | — | US | claimed |
| WO-2023150540-A1 | HYDROXAMIC ACID MACROCYCLIC AGENTS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. (US) | 2023-08-10 | — | — | WO | claimed |
| WO-2023104744-A1 | 3-((3-([1,1'-BIPHENYL]-3-YLMETHOXY)PHENOXY)METHYL)BENZONITRILE DERIVATIVES AND THE USE THEREOF | HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF E.V. (DE) | 2023-06-15 | — | — | WO | claimed |
| US-20230173112-A1 | PSMA-Targeting Ligands With Optimal Properties for Imaging and Therapy | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-06-08 | — | — | US | claimed |
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | GRUENENTHAL GMBH (DE) | 2023-01-26 | — | — | US | claimed |
| WO-2022263498-A1 | SUBSTITUTED PYRAZOLE AMIDES | Grünenthal GmbH (DE) | 2022-12-22 | — | — | WO | claimed |
| WO-2022226326-A1 | PSMA-TARGETING LIGANDS WITH OPTIMAL PROPERTIES FOR IMAGING AND THERAPY | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2022-10-27 | — | — | WO | claimed |
| CN-109789116-B | Use of SC-43 for improving fibrosis | 陈昆锋 | 2022-02-01 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173112-A1 | PSMA-Targeting Ligands With Optimal Properties for Imaging and Therapy | PSMA1, PSMA2, FOLH1 | RAF1 4851/4885KDR 3905/4885CDK8 2924/4885 |
| US-20250262335-A1 | PSMA-Targeting Ligands with Optimal Properties for Imaging and Therapy | PSMA1, PSMA2, FOLH1 | RAF1 4844/4885KDR 4008/4885CDK8 2835/4885 |
| US-20250186630-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES | FAP, FIBP, TPX2 | RAF1 1997/4885KDR 2487/4885CDK8 3533/4885 |
| US-20230302164-A1 | PSMA-Targeting Ligands With Optimal Properties for Imaging and Therapy | PSMA1, PSMA2, FOLH1 | RAF1 4844/4885KDR 4008/4885CDK8 2835/4885 |
| US-20250186632-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES | FAP, FIBP, LAP3 | RAF1 1928/4885KDR 2498/4885CDK8 2786/4885 |
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | SCN8A, SCN1A, SCN7A | RAF1 934/4885KDR 2752/4885CDK8 373/4885 |
| US-20250332296-A1 | ZWITTERIONIC METAL CHELATORS | SLC39A14, SLC7A1, SLC39A11 | RAF1 4712/4885KDR 1739/4885CDK8 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.